These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 30355736)

  • 41. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations.
    Blancas-Mejía LM; Tischer A; Thompson JR; Tai J; Wang L; Auton M; Ramirez-Alvarado M
    J Mol Biol; 2014 Jan; 426(2):347-61. PubMed ID: 24157440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.
    Wall JS; Gupta V; Wilkerson M; Schell M; Loris R; Adams P; Solomon A; Stevens F; Dealwis C
    J Mol Recognit; 2004; 17(4):323-31. PubMed ID: 15227639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.
    Oberti L; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Maritan M; Palladini G; Bolognesi M; Merlini G; Ricagno S
    Sci Rep; 2017 Dec; 7(1):16809. PubMed ID: 29196671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
    Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
    Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain.
    Davis DP; Gallo G; Vogen SM; Dul JL; Sciarretta KL; Kumar A; Raffen R; Stevens FJ; Argon Y
    J Mol Biol; 2001 Nov; 313(5):1021-34. PubMed ID: 11700059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis.
    Manabe S; Iwasaki C; Hatano M; Kametani F; Yazaki M; Nitta K; Nagata M
    BMC Nephrol; 2018 Nov; 19(1):337. PubMed ID: 30466387
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis.
    Brancaccio D; Ghiggeri GM; Braidotti P; Garberi A; Gallieni M; Bellotti V; Zoni U; Gusmano R; Coggi G
    J Am Soc Nephrol; 1995 Oct; 6(4):1262-70. PubMed ID: 8589295
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis.
    Wang J; Li J; Zhong L
    Blood Rev; 2024 Jul; 66():101207. PubMed ID: 38692939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Heat-induced native dimerization prevents amyloid formation by variable domain from immunoglobulin light-chain REI.
    Nawata M; Tsutsumi H; Kobayashi Y; Unzai S; Mine S; Nakamura T; Uegaki K; Kamikubo H; Kataoka M; Hamada D
    FEBS J; 2017 Sep; 284(18):3114-3127. PubMed ID: 28736891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
    Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
    Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tyrosine residues mediate fibril formation in a dynamic light chain dimer interface.
    DiCostanzo AC; Thompson JR; Peterson FC; Volkman BF; Ramirez-Alvarado M
    J Biol Chem; 2012 Aug; 287(33):27997-8006. PubMed ID: 22740699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular basis for insulin fibril assembly.
    Ivanova MI; Sievers SA; Sawaya MR; Wall JS; Eisenberg D
    Proc Natl Acad Sci U S A; 2009 Nov; 106(45):18990-5. PubMed ID: 19864624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains.
    Wong S; West ME; Morgan GJ
    Protein Sci; 2024 Mar; 33(3):e4871. PubMed ID: 38100259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MAK33 antibody light chain amyloid fibrils are similar to oligomeric precursors.
    Hora M; Sarkar R; Morris V; Xue K; Prade E; Harding E; Buchner J; Reif B
    PLoS One; 2017; 12(7):e0181799. PubMed ID: 28746363
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interaction between glycosaminoglycans and immunoglobulin light chains.
    Jiang X; Myatt E; Lykos P; Stevens FJ
    Biochemistry; 1997 Oct; 36(43):13187-94. PubMed ID: 9341206
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
    Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
    Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Domain Interactions Determine the Amyloidogenicity of Antibody Light Chain Mutants.
    Weber B; Hora M; Kazman P; Pradhan T; Rührnößl F; Reif B; Buchner J
    J Mol Biol; 2020 Nov; 432(23):6187-6199. PubMed ID: 33058870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains.
    Stevens FJ; Myatt EA; Chang CH; Westholm FA; Eulitz M; Weiss DT; Murphy C; Solomon A; Schiffer M
    Biochemistry; 1995 Aug; 34(34):10697-702. PubMed ID: 7662653
    [No Abstract]   [Full Text] [Related]  

  • 60. Inhibition of amyloid fibril formation in the variable domain of λ6 light chain mutant Wil caused by the interaction between its unfolded state and epigallocatechin-3-O-gallate.
    Abe Y; Odawara N; Aeimhirunkailas N; Shibata H; Fujisaki N; Tachibana H; Ueda T
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2570-2578. PubMed ID: 30251653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.